Related Experiment Video

Updated: Jan 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.2K

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

Yijun Gao1, Ann Maria1, Na Na1

  • 1Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.

Cancer Discovery
|June 23, 2019
PubMed

Insights

A novel MEK1 V211D mutation caused resistance to MEK inhibitors in colon cancer. This mutation remains sensitive to ATP-competitive MEK inhibitors, offering a new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The study investigates resistance mechanisms to targeted therapies in BRAF-mutated colon cancer.
  • Allosteric MEK inhibitors like binimetinib are used in treating such cancers.
  • The emergence of drug resistance necessitates understanding novel mutation pathways.

Purpose of the Study:

  • To identify and characterize a novel MEK1 gatekeeper mutation (V211D) conferring resistance to MEK inhibitors.
  • To elucidate the mechanism by which MEK1 V211D causes resistance to binimetinib.
  • To explore therapeutic strategies to overcome this resistance.

Main Methods:

  • Case study of a patient with BRAF K601E colon cancer treated with binimetinib and panitumumab.
  • Genetic sequencing to identify mutations in MEK1.
  • Biochemical assays to assess MEK1 catalytic activity and drug binding affinity.

Main Results:

  • A novel MEK1 V211D gatekeeper mutation was identified in a patient with BRAF K601E colon cancer.
  • MEK1 V211D confers resistance to the allosteric MEK inhibitor binimetinib by increasing catalytic activity and reducing drug affinity.
  • The MEK1 V211D mutation showed cross-resistance to tested allosteric MEK inhibitors but remained sensitive to ATP-competitive MEK inhibitors.

Conclusions:

  • The MEK1 V211D mutation represents a significant resistance mechanism to current allosteric MEK inhibitors in colon cancer.
  • ATP-competitive MEK inhibitors show promise for overcoming resistance mediated by the MEK1 V211D mutation.
  • Understanding these resistance mechanisms is crucial for developing effective and durable cancer therapies.

More Related Videos

Quantification of Colonic Stem Cell Mutations07:53

Quantification of Colonic Stem Cell Mutations

Published on: September 25, 2015

7.0K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.1K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.7K
The Colonization of Land02:22

The Colonization of Land

Changes in the environment of the early Earth drove the evolution of organisms. As prokaryotic organisms in the oceans began to photosynthesize, they produced oxygen. Eventually, oxygen saturated the oceans and entered the air, resulting in an increase in atmospheric oxygen concentration, known as the oxygen revolution approximately 2.3 billion years ago. Therefore, organisms that could use oxygen for cellular respiration had an advantage. More than 1.5 years ago, eukaryotic cells and...
37.5K